We are developing cobitolimod to help patients with ulcerative colitis live a more normal life
Ulcerative colitis (UC) is a serious and chronic inflammatory bowel disease that has no cure. Approximately 0.2 percent of the world’s population suffers from UC and the number of persons living with the disease (the prevalence) is expected to increase by 0.8 percent every year. The risk of getting inflammatory bowel diseases has increased by more than ten times over the past 75 years.
In this section you can:
- Learn more about InDex Pharmaceuticals’ drug candidate cobitolimod and its upcoming phase III clinical trials
- Read patient stories
- Find out more information about ulcerative colitis
Please use the left-hand menu to find out more.